Mass Drug Administration With Dihydroartemisinin-piperaquine and Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study

Abstract

Background: Mass drug administration (MDA) may further reduce malaria transmission in low-transmission areas. The impact of MDA on the dynamics of malaria transmission was determined in a prospective cohort study.

Methods: Annual rounds of MDA with dihydroartemisinin-piperaquine (DP) were implemented were implemented in 2014 and 2015 in six village pairs before the malaria transmission season. Blood samples were collected from residents between July and December for microscopy and nested PCR. Incidence and prevalence of infection, clinical disease, and risk of malaria reinfection post-MDA were determined.

Results: Coverage of three DP doses was 68.2% (2014) and 65.6% (2015), compliance was greater than 80%. Incidence of infection was significantly lower in 2014 (incidence rate [IR] = 0.2 per person year [PPY]) than in 2013 (IR = 1.1 PPY; P < .01); monthly infection prevalence declined in the first three months post-MDA. Clinical malaria incidence was lower in 2014 (IR = 0.1 PPY) and 2015 (IR = 0.2 PPY) than in 2013 (IR = 0.4 PPY; P < .01), but remained higher in eastern Gambia. Individuals infected before MDA had a 2-fold higher odds of reinfection post-MDA (adjusted odds ratio = 2.5, 95% confidence interval 1.5-4.3; P < .01).

Conclusions: MDA reduced malaria infection and clinical disease during the first months. The reduction was maintained in low-transmission areas, but not in eastern Gambia. Annual MDA could be followed by focal MDA targeting individuals infected during the dry season. Repeated MDA rounds, some during the dry season over larger geographical areas, may result in a more marked and sustained decrease of malaria transmission.

Keywords: clinical malaria; dihydroartemisinin-piperaquine; gametocytes; malaria infection; mass drug administration.

Figure 1.

Study sites and monthly malaria prevalence and incidence of infection by region, before (2013) and after (2014) 1 annual MDA round. Abbreviations: DP, dihydroartemisinin-piperaquine; IR, incidence rate; MDA, mass drug administration; PPY, per person, per year.

Figure 2.

Study flow diagram.

Figure 3.

Monthly prevalence and density of Plasmodium falciparum infections, before and after 1 MDA round. Abbreviations: DP, dihydroartemisinin-piperaquine; MDA, mass drug administration.

Figure 4.

Monthly incidence of clinical malaria by region, before (2013) and after (2014) 1 annual MDA round. Abbreviations: DP, dihydroartemisinin-piperaquine; IR, incidence rate; MDA, mass drug administration; PPY, per person year.